{
    "clinical_study": {
        "@rank": "41808", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 - Exposed Cohort", 
                "description": "Pregnant women with a current diagnosis of RA or Crohn's Disease who have used Cimzia (certolizumab pegol) in the first trimester of pregnancy for any length of time from the date of conception."
            }, 
            {
                "arm_group_label": "Cohort 2 - Diseased Comparison Cohort", 
                "description": "Pregnant women with a current diagnosis of RA or Crohn's Disease who have or have not used Cimzia (certolizumab pegol) or any tumor necrosis factor (TNF)-antagonist during the current pregnancy."
            }, 
            {
                "arm_group_label": "Cohort 3 - Non-Diseased Comparison Cohort", 
                "description": "Pregnant women without a current diagnosis of an autoimmune disease and who have not used Cimzia (certolizumab pegol) or any TNF-antagonist at any time in pregnancy, nor have they been exposed to any known human teratogen during pregnancy."
            }, 
            {
                "arm_group_label": "Group 4 -Cimzia Registry, Not Qualified for the Cohort Study", 
                "description": "Women who have used Cimzia (certolizumab pegol) for any length of time following the first day of the last menstrual period until the end of pregnancy who do not qualify for the prospective cohort study."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the OTIS Autoimmune Diseases in Pregnancy Study is to monitor planned and\n      unplanned pregnancies exposed to certain medications, to evaluate the possible teratogenic\n      effect of these medications and to follow live born infants for five years after birth.\n      With respect to fetal outcome, it is important to evaluate the spectrum of outcomes that may\n      be relevant to a medication exposure during pregnancy, and these include both easily\n      recognizable defects which are visible at birth, as well as more subtle or delayed defects\n      that may not be readily identifiable without special expertise and observation beyond the\n      newborn period."
        }, 
        "brief_title": "OTIS Autoimmune Diseases in Pregnancy Project", 
        "completion_date": {
            "#text": "December 2022", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Crohn's Disease", 
            "Rheumatoid Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Autoimmune Diseases", 
                "Crohn Disease"
            ]
        }, 
        "detailed_description": {
            "textblock": "The purpose of the OTIS Autoimmune Diseases in Pregnancy Project, Cimzia Pregnancy Exposure\n      Registry is to follow pregnant women with or without rheumatoid arthritis (RA) or Crohn's\n      Disease (CD) who have or have not been treated with Cimzia during pregnancy to evaluate the\n      possible effect of these diseases, and or this medication on the pregnancy outcome including\n      child development and growth up to five years of age."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Currently pregnant"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pregnant women who reside in the United States or Canada."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797224", 
            "org_study_id": "RA0023"
        }, 
        "intervention_browse": {
            "mesh_term": "Immunoglobulin Fab Fragments"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Autoimmune disease", 
            "certolizumab pegol", 
            "Cimzia", 
            "pregnancy", 
            "birth defect", 
            "birth outcome", 
            "TNF", 
            "Tumor necrosis factor"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "link": {
            "description": "Official Reserch website of the Organization of Teratology Information Specialists Coordinated at the Univesity of California, San Diego", 
            "url": "http://www.pregnancystudies.org"
        }, 
        "location": {
            "contact": {
                "email": "d4johnson@ucsd.edu", 
                "last_name": "Diana Johnson, MS", 
                "phone": "877-311-8972"
            }, 
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92093"
                }, 
                "name": "University of California, San Diego"
            }, 
            "investigator": {
                "last_name": "Christina Chambers, MPH, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "4", 
        "official_title": "Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project", 
        "overall_contact": {
            "email": "d4johnson@ucsd.edu", 
            "last_name": "Diana Johnson, MS", 
            "phone": "877-311-8972"
        }, 
        "overall_contact_backup": {
            "email": "chchambers@ucsd.edu", 
            "last_name": "Christina Chambers, MPH, PhD", 
            "phone": "858-246-1740"
        }, 
        "overall_official": {
            "affiliation": "University of California, San Diego", 
            "last_name": "Christina Chambers, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of the study is to evaluate the effect of certain medications when used in the first trimester of pregnancy with respect to major structural birth defects.", 
            "measure": "Major malformations", 
            "safety_issue": "Yes", 
            "time_frame": "Duration of pregnancy and up to 1 year of life"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797224"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, San Diego", 
            "investigator_full_name": "Christina Chambers", 
            "investigator_title": "Professor, Co-Director Center for Promotion of Maternal Health and Infant Development", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "One secondary objective of the study is to evaluate the effects of certain medications when used in the first trimester of pregnancy with respect to potential minor malformations.", 
                "measure": "Minor malformations", 
                "safety_issue": "Yes", 
                "time_frame": "At dysmorphological exam which will occur at one time point between birth and 5 years of age"
            }, 
            {
                "description": "Another objective of the study is to evaluate the effects of certain medications when used in the first trimester of pregnancy with respect to potential minor malformations", 
                "measure": "Pregnancy Outcome", 
                "safety_issue": "Yes", 
                "time_frame": "Duration of pregnancy and up to 1 year of life"
            }, 
            {
                "description": "Pre- and post-natal fetal and infant growth, health and development", 
                "measure": "Infant follow-up", 
                "safety_issue": "Yes", 
                "time_frame": "Duration of pregnancy and up to 5 years of life"
            }
        ], 
        "source": "University of California, San Diego", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "The Organization of Teratology Information Specialists", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "UCB, Inc.", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "University of California, San Diego", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}